AtLAS-A Trial
Phase 4
60
about 5.7 years
12–17
1 site in OH
What this study is about
This trial is testing whether duloxetine or escitalopram are effective in treating anxiety and depression in adolescents. It involves a double-blind treatment period followed by an open-label, naturalistic follow-up phase lasting 2069 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Duloxetine
- 2.Take Escitalopram
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
duloxetine (SNRI; increases serotonin and norepinephrine levels), escitalopram (SSRI; increases serotonin availability)
oral (Delayed Release Oral Capsule), oral (Oral Tablet)
Primary: Change from Baseline in Pediatric Anxiety Rating Scale (PARS) severity score, Change from Baseline in the Clinical Global Impression of Severity (CGI-S)
Psychiatry / Mental Health